Targeting human secretory phospholipase A2 with designed peptide inhibitors for inflammatory therapy

Journal of Drug Targeting

Volumn 23, Issue 2, 2015, Pages 140-146

  Wang, Peng ^a   Li, Yongtao ^b   Shao, Qiuping ^a   Zhou, Wenqin ^a   Wang, Kuifeng ^b  

^a JIANGSU UNIVERSITY   (China)

^b Biosystem Medical Technology Co Ltd   (China)

Author keywords

Inflammation; Peptide inhibitor; Phospholipase A2; Rational drug targeting

Indexed keywords

AMINO ACID; CLARA CELL PROTEIN; PENTAPEPTIDE; PENTAPEPTIDE LLLGS; PHOSPHOLIPASE A2 INHIBITOR; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT; PROTEIN BINDING; UTEROGLOBIN;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; HYDROPHOBICITY; INFLAMMATION; KINETICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG DESIGN; ENZYME ACTIVE SITE; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CATALYTIC DOMAIN; DRUG DESIGN; HUMANS; KINETICS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PEPTIDE FRAGMENTS; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2, SECRETORY; PROTEIN BINDING; UTEROGLOBIN;

EID: 84921295106     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.959019     Document Type: Article

References (36)

1. Ashley NT, Weil ZM, Nelson RJ. Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst 2012;43:385-406.
2. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009;50:S237-42.
3. Meyer MC, Rastogi P, Beckett CS, McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 2005;11:1301-12.
4. Mahalka AK, Kinnunen PK. Class specific peptide inhibitors for secretory phospholipases A2. Biochem Biophys Res Commun 2013;436:349-53.
5. Zhou P, Wang C, Ren Y, et al. Computational peptidology: a new and promising approach to therapeutic peptide design. Curr Med Chem 2013;20:1985-96.
6. Chandra V, Kaur P, Srinivasan A, Singh TP. Three-dimensional structure of a presynaptic neurotoxic phospholipase A2 from Daboia russelli pulchella at 2.4 A˚ resolution. J Mol Biol 2000;296: 1117-26.
7. Chandra V, Jasti J, Kaur P, et al. Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr D 2002;58:1813-19.
8. Singh RK, Ethayathulla AS, Jabeen T, et al. Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 angstroms resolution. J Drug Target 2005;13:113-19.
9. Singh RK, Somvanshi N, Sharma S, et al. Structural elements of ligand recognition site in secretory phospholipase A2 and structurebased design of specific inhibitors. Curr Top Med Chem 2007;7:757-64.
10. Singh RK, Vikram P, Makker J, et al. Design of specific peptide inhibitors for group I phospholipase A2: structure of a complex formed between phospholipase A2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9A˚ resolution reveals unique features. Biochemistry 2003;42:11701-6.
11. Jorens PG, Sibille Y, Goulding NJ, et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 1995;8:1647-53.
12. Hansford KA, Reid RC, Clark CI, et al. D-tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem 2003;4:181-5.
13. Thwin MM, Ong WY, Fong CW, et al. Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp Brain Res 2003;150:427-33.
14. Umland TC, Swaminathan S, Furey W, et al. Refined structure of rat Clara cell 17 kDa protein at 3.0 A˚ resolution. J Mol Biol 1992;224:441-8.
15. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins 2003;52:80-7.
16. Word JM, Lovell SC, Richardson JS, Richardson DC. Asparagine and glutamine: using hydrogen atom contacts in the choice of sidechain amide orientation. J Mol Biol 1999a;285:1735-47.
17. Rostkowski M, Olsson MH, Søndergaard CR, Jensen JH. Graphical analysis of pH-dependent properties of proteins predicted using PROPKA. BMC Struct Biol 2011;11:6.
18. London N, Raveh B, Cohen E, et al. Rosetta FlexPepDock web server - high resolution modeling of peptide-protein interactions. Nucleic Acids Res 2011;39:W249-53.
19. Raveh B, London N, Schueler-Furman O. Sub-angstrom modeling of complexes between flexible peptides and globular proteins. Proteins 2010;78:2029-40.
20. Duan Y, Wu C, Chowdhury S, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensedphase quantum mechanical calculations. J Comput Chem 2003;24:1999-2012.
21. Darden T, York D, Pedersen L. Particle mesh Ewald and N.log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089-92.
22. Ryckaert J, Ciccotti G, Berendsen HJC. Numerical-integration of Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327-41.
23. Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889-97.
24. Pierce BG, Wiehe K, Hwang H, et al. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics 2014;30:1771-3.
25. Church WB, Inglis AS, Tseng A, et al. A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition. J Biol Chem 2001;276:33156-64.
26. Thwin MM, Satyanarayanajois SD, Nagarajarao LM, et al. Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling. J Med Chem 2007;50:5938-50.
27. Word JM, Lovell SC, LaBean TH, et al. Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms. J Mol Biol 1999b;285:1711-33.
28. Stein A, Aloy P. Contextual specificity in peptide-mediated protein interactions. PLoS One 2008;3:e2524.
29. Morrison KL, Weiss GA. Combinatorial alanine-scanning. Curr Opin Chem Biol 2001;5:302-7.
30. Bi J, Yang H, Yan H, et al. Knowledge-based virtual screening of HLA-A∗0201-restricted CD8+ T-cell epitope peptides from herpes simplex virus genome. J Theor Biol 2011;281:133-9.
31. Xiang Z, Honig B. Extending the accuracy limits of prediction of side-chain conformations. J Mol Biol 2001;311:421-30.
32. Hou T, Chen K, McLaughlin WA, et al. Computational analysis and prediction of the binding motif and protein interacting partners of the Abl SH3 domain. PLoS Comput Biol 2006;2:e1.
33. Ni Z, Chen H, Qi X, Jin R. Why is substrate peptide binding unsusceptible to multidrug-resistant mutations in HIV-1 protease? A structural and energetic analysis. Int J Pept Res Ther 2014;20:43-51.
34. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127-34.
35. Zhou P, Zou J, Tian F, Shang Z. Fluorine bonding - how does it work in protein-ligand interactions? J Chem Inf Model 2009;49:2344-55.
36. Zhou P, Huang J, Tian F. Specific noncovalent interactions at protein-ligand interface: implications for rational drug design. Curr Med Chem 2012;19:226-38.